Using entecavir to prevent hepatitis B flare-up in gastrointestinal cancer patients
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether giving the antiviral drug entecavir before or at the first sign of hepatitis B reactivation can prevent liver problems in gastrointestinal cancer patients who are inactive hepatitis B carriers and are starting chemotherapy or immunotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have a gastrointestinal cancer (such as colorectal, stomach, esophageal, liver, pancreatic, or bile duct cancer) that cannot be removed by surgery or has spread.
- You are about to start your first, second, or third round of chemotherapy or immunotherapy (PD-1/PD-L1 drugs).
- You are physically active enough to handle daily activities (ECOG score 0-2).
- You have had hepatitis B in the past or are a chronic carrier, but the virus is currently inactive (negative HBV-DNA test).
- Your liver function and major organ function are within normal range.
- You have not had liver cirrhosis or a prior hepatitis B flare-up, and you are not on hepatitis B treatment now.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares three hepatitis B (HBV) medicines to see which treatment helps people with a severe liver flare. You may be eligible if you have confirmed HBV and lab results showing significant liver stress.
This trial tests whether switching from the regular entecavir pill to a new orally dissolving version works just as well and is safe for patients who have had a liver transplant due to hepatitis B. If you've been stable on entecavir, this could be a convenient alternative.
This study compares two ways of managing hepatitis B while you receive immunotherapy for liver cancer: one group gets a single antiviral drug (TAF), the other gets two antiviral drugs (ETV and TAF). The goal is to see which approach better supports the immunotherapy and improves outcomes.
This study is looking at how well antiviral treatments work to prevent liver cancer in people with chronic hepatitis B who have a family history of the disease. If you are over 30 and taking antiviral medication, you may be able to join.
This trial tests whether taking the antiviral medicine entecavir before and after a stem cell transplant can prevent hepatitis B from “waking up” again. It may help protect your liver during a high-risk treatment period.
This study compares two treatments for children aged 3 to 6 with chronic hepatitis B. One group gets the standard medicine entecavir, and the other gets entecavir plus a medicine that helps the immune system fight the virus (peginterferon). The goal is to see if the combination works better.
Hear when a new Gastrointestinal Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.